Browsing by Author "Kaplan, Muhammet Ali"

Now showing 1 - 4 of 4

The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; Multicenter observational study
(Imprimatur Publications, 2011) Saip, Pınar Mualla; Keskin, Serkan; Özkan, Metin; Kaplan, Muhammet Ali; Aydoǧan, Fatma; Gönüllü Demirağ, Güzin; Uzunoǧlu, Sernaz; Engin, Hüseyin Bülent; Başaran, Gül Atalay; Gü̈ler, Nilüfer E.; Uygun, Kazım M.; Demirkan, Binnaz Hatice Miraç; Özdemir, Feyyaz; Salepçi, Taflan; Çiçin, İrfan; Çubukçu, Erdem; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 53986153800
Purpose: To determine the time elapsed between the first notification of the disease and the access to the diagnosis and treatment modalities and the associated factors in female patients with breast cancer in Turkey. Methods: Data was acquired from a questionnaire involving 535 patients who applied to 14 various oncology clinics in Turkey between 1st and 28th of February 2010. Analyses were performed by the participating clinics and were divided into 3 groups: centers located in metropolitan areas formed group I (n=161), those located in Marmara and central Anatolia region formed group 2 (n=189), and centers located in Karadeniz and East-Southeast Anatolia region formed group 3 (n=185). The groups of these centers were formed according to the socioeconomic development of the provinces. Results: The median patient age was 48 years, 56.1% of patients were less than 50 years of age. Eighty-five percent of the patients detected a mass in their breast by self examination and 27% of the patients older than 50 years never had breast imaging until the definite diagnosis was established. The median time elapsed between disease noticed by the patient and application to a health care center was 10 days, between application and biopsy 19 days, between biopsy and surgery 10 days, and between surgery and systemic therapy 31 days. The median time elapsed between patients applying for surgery in groups I and 2 centers was 11 and 21 days, respectively (p=0.01). The median time elapsed between biopsy and surgery in groups 1,2 and 3 centers was 14,1.5, and 12 days, respectively (p<0.05). Conclusion: A high level of awareness regarding breast cancer in our country is related with the time that is defined as 10 days between disease recognition and medical application. The time elapsed between the application and biopsy, surgery and systemic therapy was longer compared with the corresponding figures in developed countries.
Biologic subtypes and first relapse pattern in curative surgery performed breast cancer patients: Study of Anatolian Society of Medical Oncology
(Lippincott Williams & Wilkins, 2013-05-20) Kaplan, Muhammet Ali; Arslan, Ülkü Yalçıntaş; Işıkdoğan, Abdurrahman; Öksüzoğlu, Berna; İnanç, Mevlüde; Akman, Tülay; İnal, Ali; Çankır, Havva Yeşil; Küçüköner, Mehmet; Budakoğlu, Burçin; Özkan, Metin; Yılmaz, Uğur; Baykara, Meltem; Yazılıtaş, Doğan; Ersoy, Uğur; Bilici, Mehmet; Çubukcu, Erdem; Yazıcı, Ozan; Suner, Ali; Demirci, Umut; ÇUBUKÇU, ERDEM; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; ETP-1691-2022
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
(Imprimatur Publications, 2020-07-01) Hacıoğlu, Muhammet Bekir; Köstek, Osman; Karabulut, Senem; Taştekin, Didem; Göksu, Sema Sezgin; Alandağ, Celal; Akagündüz, Baran; Bilgetekin, İrem; Yildiz, Birol; Köse, Fatih; Kaplan, Muhammet Ali; Gülmez, Ahmet; Doğan, Ender; Güven, Deniz Can; Gürbüz, Mustafa; Ergun, Yakup; Karaagaç, Mustafa; Demiray, Atike Gökçen; Türker, Sema; Sakalar, Teoman; Özkul, Özlem; Telli, Tugba Akın; Şahin, Süleyman; Kılıçkap, Saadettin; Bilici, Ahmet; Erdoğan, Bulent; Cicin, Irfan; CANER, BURCU; Caner, Burcu; Şahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim; AAE-8549-2022; HJH-6371-2023
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included.Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85).Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.
The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study
(Imprimatur Publications, 2019-05-01) Kaplan, Muhammet Ali; Oruç, Zeynep; Gümüş, Mahmut; Özaydm, Şükrü; Elkıran, Emin Tamer; Dine, Nur Şener; Sakin, Abdullah; Berk, Veli; Akman, Tülay; Aytekin, Aydin; Yazılıtaş, Doğan; Dane, Faysal; İmamoğlu, Gökşen İnanç; Çubukcu, Erdem; Işıkdoğan, Abdurrahman; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; ERK-4356-2022
Purpose: To analyze the reliability and the effectiveness of chemotherapy and prognostic factors for survival in patients with HER2 (human epidermal growth receptor 2) negative early-stage breast cancer treated with adjuvant sequential anthracycline-based chemotherapy and paclitaxel.Methods: This analysis retrospectively evaluated the medical records of 756 HER2 negative early-stage breast cancel-patients who received adjuvant sequential anthracycline-based chemotherapy and weekly paclitaxel in 15 medical oncology centers in Turkey between 2008-2015. Estrogen receptor (ER), progesterone receptor (PR), HER2, age, tumor size and grade, nodal status, perineural and lymphatic invasion, disease-free survival (DFS) and overall survival (OS) were analyzed.Results: The median patient age was 50 years (22-82). Median follow up period was 46 months (13-82). The rates of recurrence and death detected in this period were 14.8% and 7.4%, respectively.Median OS and PFS were not reached in this period. Five-year DFS and OS rates were 87% and 89%, respectively. Age (OR:0.35, 95%CI 0.12-0.96, p=0.04), PR status (OR:.0.44, 95%CI 0.18-1, p=0.05), lymphatic invasion (OR:.2.6, 95%CI 0.97-7.4, p=0.05) were independent prognostic factors.Most common grade 3-4 toxicides were fatigue (6.7%), neutropenia (1.7%) and nausea (1.3%). Neutropenic fever developed in 1.8% o f the patients and peripheral neuropathy in 16.9%. Dose reduction was necessary for 10%of the patients due to grade 3-4 toxicity, whereas postponement of chemotherapy was neccessary for 7% of the patients.Conclusions: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen.